ArticleOncogene2006
Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 74 citations in OpenAlex.
- Identification of A p300-SP1-BRD4 Transcriptional Axis as a Key Driver of AR Hyperactivation in Polycystic Ovarian Syndrome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Genitourinary system related tumors and coronary atherosclerosis risk: Evidence from a Mendelian randomization study on multi-cohorts.Translational oncology · 2025Article
- Epigenetic developmental mechanisms underlying sex differences in cancer.The Journal of clinical investigation · 2024Review
- Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer.Cancers · 2022Review
- A Src-H3 acetylation signaling axis integrates macrophage mechanosensation with inflammatory response.Biomaterials · 2021Article
- Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.Cancers · 2017Review
- Epigenetic control of cancer by neuropeptides.Biomedical reports · 2017Article
- Mechanisms of resistance in castration-resistant prostate cancer (CRPC).Translational andrology and urology · 2015Review
- p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis.Cancer research · 2014Article
- SRC: marker or actor in prostate cancer aggressiveness.Frontiers in oncology · 2014Review
- Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.CNS & neurological disorders drug targets · 2013Review
- Multiple Sites of Type II Site Ligand (Luteolin and BMHPC) Regulation of Gene Expression in PC-3 Cells.International journal of biomedical science : IJBS · 2012Article
- Androgen receptor co-activators in the regulation of cellular events in prostate cancer.World journal of urology · 2012Review
- Post-translational modifications of nuclear receptors and human disease.Nuclear receptor signaling · 2012Review
- Regulators of gene expression as biomarkers for prostate cancer.American journal of cancer research · 2012Article
- SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2011Article
- An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha.Molecular endocrinology (Baltimore, Md.) · 2010Article
- Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.Oncogene · 2010Article
- The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth.Cancer research · 2009Article
- Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.Endocrine-related cancer · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Androgen receptor signaling in prostate cancer cells is augmented by the androgen receptor (AR) coactivator p300, which transactivates and acetylates the AR in the presence of dihydrotestosterone (DHT). As prostate cancer (PC) cells progress to androgen independence, AR signaling remains intact, indicating that other factors stimulate AR activities in the absence of androgen. We previously reported that neuropeptide growth factors could transactivate the AR in the presence of very low concentrations of DHT. Here, we examine the involvement of p300 in neuropeptide activation of AR signaling. Transfection of increasing concentrations of p300 in the presence of bombesin into PC-3 cells resulted in a linear increase in AR transactivation, suggesting that p300 acts as a coactivator in neuropeptide-mediated AR transactivation. P300 is endowed with histone acetyltransferase (HAT) activity. Therefore, we examine the effect of bombesin on p300 HAT activity. At 4 h after the addition of bombesin, p300 HAT activity increased 2.0-fold (P<0.01). Incubation with neutral endopeptidase, which degrades bombesin, or bombesin receptor antagonists blocked bombesin-induced p300 HAT activity. To explore the potential signaling pathways involved in bombesin-induced p300 HAT activity, we examined Src and PKCdelta pathways that mediate bombesin signaling. Inhibitors of Src kinase activity or Src kinase siRNA blocked bombesin-induced p300 HAT activity, whereas PKCdelta inhibitors or PKCdelta siRNA significantly increased bombesin-induced p300 HAT activity suggesting that Src kinase and PKCdelta kinase are involved in the regulation of p300 HAT activity. As AR is acetylated in the presence of 100 nM DHT, we next examined whether bombesin-induced p300 HAT activity would result in enhanced AR acetylation. Bombesin-induced AR acetylation at the same motif KLKK observed in DHT-induced acetylation. Elimination of p300 using p300 siRNA reduced AR acetylation, demonstrating that AR acetylation was mediated by p300. AR acetylation results in AR transactivation and the expression of the AR-regulated gene prostate-specific antigen (PSA). Therefore, we examined bombesin-induced AR transactivation and PSA expression in the presence and absence of p300 siRNA and found inhibition of p300 expression reduced bombesin-induced AR transactivation and PSA expression. Together these results demonstrate that bombesin, via Src and PKCdelta signaling pathways, activates p300 HAT activity which leads to enhanced acetylation of AR resulting in increased expression of AR-regulated genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.